https://ir.tuhurabio.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_0b4577ffa47b2b3b138998038d9a2607/tuhurabio/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.tuhurabio.com/news-events/press-releases/detail/50/tuhura-biosciences-receives-fda-study-may-proceed-notice-and-ind-clearance-for-the-evaluation-of-its-tbs-2025-vista-inhibiting-antibody-in-molecularly-defined-subsets-of-aml-and-other-blood-related-cancers Mon, 14 Sep 26 07:45:00 -0400 https://ir.tuhurabio.com/news-events/press-releases/detail/50/tuhura-biosciences-receives-fda-study-may-proceed-notice-and-ind-clearance-for-the-evaluation-of-its-tbs-2025-vista-inhibiting-antibody-in-molecularly-defined-subsets-of-aml-and-other-blood-related-cancers https://ir.tuhurabio.com/news-events/press-releases/detail/49/tuhura-biosciences-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference Tue, 08 Sep 26 07:45:00 -0400 https://ir.tuhurabio.com/news-events/press-releases/detail/49/tuhura-biosciences-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference https://ir.tuhurabio.com/news-events/press-releases/detail/48/tuhura-biosciences-reports-second-quarter-2026-financial-results-and-provides-a-corporate-update Fri, 14 Aug 26 07:45:00 -0400 https://ir.tuhurabio.com/news-events/press-releases/detail/48/tuhura-biosciences-reports-second-quarter-2026-financial-results-and-provides-a-corporate-update https://ir.tuhurabio.com/news-events/press-releases/detail/47/tuhura-biosciences-to-present-at-canaccord-genuitys-46th-annual-growth-conference Wed, 22 Jul 26 07:40:00 -0400 https://ir.tuhurabio.com/news-events/press-releases/detail/47/tuhura-biosciences-to-present-at-canaccord-genuitys-46th-annual-growth-conference https://ir.tuhurabio.com/news-events/press-releases/detail/46/tuhura-biosciences-files-investigational-new-drug-application-for-evaluation-of-the-tbs-2025-vista-inhibiting-antibody-in-molecularly-defined-subsets-of-aml-and-other-blood-related-cancers Mon, 15 Jun 26 07:45:00 -0400 https://ir.tuhurabio.com/news-events/press-releases/detail/46/tuhura-biosciences-files-investigational-new-drug-application-for-evaluation-of-the-tbs-2025-vista-inhibiting-antibody-in-molecularly-defined-subsets-of-aml-and-other-blood-related-cancers https://ir.tuhurabio.com/news-events/press-releases/detail/45/tuhura-biosciences-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update Fri, 15 May 26 17:00:00 -0400 https://ir.tuhurabio.com/news-events/press-releases/detail/45/tuhura-biosciences-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update https://ir.tuhurabio.com/news-events/press-releases/detail/44/tuhura-biosciences-to-present-at-the-4th-annual-h-c-wainwright-bioconnect-investor-conference Tue, 12 May 26 07:30:00 -0400 https://ir.tuhurabio.com/news-events/press-releases/detail/44/tuhura-biosciences-to-present-at-the-4th-annual-h-c-wainwright-bioconnect-investor-conference https://ir.tuhurabio.com/news-events/press-releases/detail/43/tuhura-biosciences-announces-50-million-credit-facility-and-royalty-transaction-extending-anticipated-cash-runway-into-2028 Wed, 22 Apr 26 07:30:00 -0400 https://ir.tuhurabio.com/news-events/press-releases/detail/43/tuhura-biosciences-announces-50-million-credit-facility-and-royalty-transaction-extending-anticipated-cash-runway-into-2028 https://ir.tuhurabio.com/news-events/press-releases/detail/42/tuhura-biosciences-appoints-amanda-garofalo-mshs-as-senior-vice-president-of-clinical-operations Tue, 07 Apr 26 07:45:00 -0400 https://ir.tuhurabio.com/news-events/press-releases/detail/42/tuhura-biosciences-appoints-amanda-garofalo-mshs-as-senior-vice-president-of-clinical-operations https://ir.tuhurabio.com/news-events/press-releases/detail/41/tuhura-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update Wed, 01 Apr 26 07:45:00 -0400 https://ir.tuhurabio.com/news-events/press-releases/detail/41/tuhura-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update